Page last updated: 2024-11-05

laxagetten 4,4'-diacetoxydiphenylpyridylemethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID29321
CHEMBL ID1909288
SCHEMBL ID3054943
MeSH IDM0041755

Synonyms (30)

Synonym
trisatin
4,4'-(1-acetyl-2-oxoindolin-3-ylidene)diphenyl di(acetate)
1-acetyl-3,3-bis(p-hydroxyphenyl)oxindole diacetate
2h-indol-2-one, 1,3-dihydro-1-acetyl-3,3-bis(4-(acetyloxy)phenyl)-
phenisatin
17,17-dimethyl-18-norandrost-4,13-dien-3-one
2h-indol-2-one, 1-acetyl-3,3-bis(4-(acetyloxy)phenyl)-1,3-dihydro-
triacetyldiphenolisatin
laxagetten
laxagen
laxagetten 4,4'-diacetoxydiphenylpyridylemethane
1-acetyl-3,3-bis(4-(acetyloxy)phenyl)-1,3-dihydro-2h-indol-2-one
brn 0365442
einecs 242-638-4
trialax
4,4'-(1-acetyl-2-oxo-3-indolinyliden)bis(phenylacetat)
isatex
dissilax-zaepfchen
neo-hollaxans
[4-[1-acetyl-3-(4-acetyloxyphenyl)-2-oxoindol-3-yl]phenyl] acetate
18869-73-3
unii-zhj4jhl6hb
zhj4jhl6hb ,
0-21-00-00619 (beilstein handbook reference)
CHEMBL1909288
2h-indol-2-one, 1-acetyl-3,3-bis[4-(acetyloxy)phenyl]-1,3-dihydro-
phenisatin [who-dd]
SCHEMBL3054943
DTXSID2066434
Q27295527

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]